InMed Pharmaceuticals (INM) Cash from Financing Activities (2020 - 2026)

InMed Pharmaceuticals' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $231675.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 92.07% year-over-year to $231675.0 in Q1 2026; TTM through Mar 2026 was $8.3 million, a 101.84% increase from a year earlier, with the FY2025 full-year figure at $12.3 million, up 163.66% from the prior year.
• Cash from Financing Activities rose to $231675.0 in Q1 2026 per INM's latest filing, from -$137178.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $8.2 million in Q2 2025 and bottomed at -$137178.0 in Q3 2025.
• The 5-year median for Cash from Financing Activities is $588380.0 (2024), against an average of $2.3 million.
• Across the five-year window, Cash from Financing Activities slumped 117.31% in 2023 and soared 4644531.25% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $5.3 million in 2022, then plunged by 101.2% to -$63697.0 in 2023, then jumped by 631.46% to $338521.0 in 2024, then slumped by 140.52% to -$137178.0 in 2025, then soared by 268.89% to $231675.0 in 2026.
• Per Business Quant, the three latest INM Cash from Financing Activities figures stand at $231675.0 (Q1 2026), -$137178.0 (Q3 2025), and $8.2 million (Q2 2025).